Background/Aims: It is relevant to investigate health-related quality of life (HRQOL) in dialysis and chronic kidney disease (CKD) patients in order to optimise treatment. The aim of this study was to investigate HRQOL in dialysis and CKD patients, to compare results from patients treated with hemodialysis (HD) and peritoneal dialysis (PD) and to investigate the prediction of dialysis quality control parameters (blood hemoglobin, plasma albumin, and Kt/V) and tobacco smoking in disease-specific HRQOL. Methods: Seventy-one HD, 59 PD, and 63 CKD patients participated in the study. Dialysis quality control parameters were measured and the patients completed the questionnaire Kidney Disease Quality Of Life. Results: PD patients rated Dialysis Staff Encouragement and Patient Satisfaction better than HD patients (p≤ 0.05). Dialysis patients scored significant lower than the general population in all generic HRQOL scales (p ≤ 0.01), whereas CKD patients scored lower than the general population in 5 of 8 scales (p ≤ 0.05). The dialysis quality parameters did not predict dialysis patients’ disease specific HRQOL, but tobacco consumption was independently associated with low scores on a number of HRQOL scales. Conclusion: Based on the results, it is suggested to include elements of HRQOL as a supplement to standard quality control parameters. It is also suggested routinely to include information of the beneficial effects of physical activity already in the predialysis program, and to focus on smoking as a very important risk factor.

Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB: Health-related quality of life, depression symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002;40:1185–1194.
Merkus PM, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. Am J Kidney Dis 1997;29:584–592.
Molsted S, Aadahl M, Schou L, Eidemak I: Self-rated health and employment status in chronic hemodialysis patients. Scand J Urol Nephrol 2004;38:174–178.
Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). Med Care 1992;30:473–483.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the Kidney Disease Quality of Life (KDQOL™-SF) instrument. Qual Life Res 1994;3:329–338.
Carmichael P, Popoola J, John I, Stevens PE, Carmichael AR: Assessment of quality of life in a single centre dialysis population using the KDQOL-SF™ Questionnaire. Qual Life Res 2000;9:195–205.
Kutner NG, Zhang R, Barnhart H, Collins AJ: Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2005;20:2159–2167.
Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C: Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important deter- minants? Clin Nephrol 2003;60:341–351.
Klang B, Clyne N: Well-being and functional ability in uraemic patients before and after having started dialysis treatment. Scand J Caring Sci 1997;11:159–166.
Korevaar JC, Jansen MAM, Merkus MP, Dekker FW, Boeschoten EW, Krediet RT: Quality of life in predialysis end-stage renal disease patients at the initiation of dialysis therapy. Perit Dial Int 2000;20:69–75.
Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD Study. Am J Kidney Dis 2005;45:658–666.
Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, Meyer KB, Levey AS. Comorbidity assessment using the index of coexistent diseases in a multicenter clinical trial. Kidney Int 2001;60:1498–1510.
Bjorner JB, Damsgaard MT, Watt T, Bech P, Rasmussen NK, Kristensen TS, Modvig J, Thuneborg K: Dansk manual til SF-36. København, LIF, 1997.
Molsted S, Heaf J, Prescott L, Eidemak I: Reliability testing of the Danish version of the Kidney Disease Quality of Life Short Form™. Scand J Urol Nephrol 2005;39:498–502.
Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR: Patient ratings of dialysis care with peritoneal dialysis vs. hemodialysis. JAMA 2004;291:697–703.
Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB; HEMO Study Group: Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 2004;66:355–366.
Eidemak I, Haaber AB, Feldt-Rasmussen B, Kanstrup IL, Strandgaard S: Exercise training and the progression of chronic renal failure. Nephron 1997;75:36–40.
Fitts SS, Guthrie MR, Blagg CR: Exercise coaching and rehabilitation counseling improve quality of life for predialysis and dialysis patients. Nephron 1999;82:115–121.
Clyne N, Ekholm J, Jogestrand T, Lins LE, Pehrsson SK: Effects of exercise training in predialytic uremic patients. Nephron 1991;59:84–89.
Heiwe S, Tollbäck A, Clyne N: Twelve weeks of exercise training increases muscle function and walking capacity in elderly predialysis patients and healthy subjects. Nephron 2001;88:48–56.
Foley RN, Herzog CA, Collins AJ: Smoking and cardiovascular outcomes in dialysis patients. Kidney Int 2003;63:1462–1467.
Monitorering af rygevaner, 2003, for Sundhedsstyrelsen. Hjerteforeningen, Danmarks Lungeforening og Kræftens Bekæmpelse.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.